Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan Westerink

Showing results (31-40 of 118) with videos related to

Pageof 12
Sort By:
European Journal of Preventive Cardiology|July 2, 2015
Relationship between recurrent miscarriage and early preterm delivery and recurrent events in patients with manifest vascular disease: The SMART studyKarst Y Heida, Maria Ph Koster, Arie Franx, et al.
Diabetes, Obesity & Metabolism|November 4, 2016
Effect modification in the association between glycated haemoglobin and cardiovascular disease and mortality in patients with type 2 diabetesSanne N van Munster, Yolanda van der Graaf, Harold W de Valk, et al.
Diabetes Care|February 24, 2018
Predicting the Effect of Fenofibrate on Cardiovascular Risk for Individual Patients With Type 2 DiabetesCharlotte Koopal, Frank L J Visseren, Jan Westerink, et al.
The American Journal of Cardiology|January 3, 2015
Effect of statin therapy on incident type 2 diabetes mellitus in patients with clinically manifest vascular diseaseAnton P van de Woestijne, Yolanda van der Graaf, Jan Westerink, et al.
Cardiovascular Diabetology|October 18, 2017
Pioglitazone and the secondary prevention of cardiovascular disease. A meta-analysis of randomized-controlled trialsMarit de Jong, H Bart van der Worp, Yolanda van der Graaf, et al.
BMJ Open|May 19, 2021
Relationship between classic vascular risk factors and cumulative recurrent cardiovascular event burden in patients with clinically manifest vascular disease: results from the UCC-SMART prospective cohort studyTamar Irene de Vries, Jan Westerink, Michiel L Bots, et al.
Journal of the American College of Cardiology|June 21, 2005
Is the association between flow-mediated dilation and cardiovascular risk limited to low-risk populations?Daniel R Witte, Jan Westerink, Eelco J de Koning, et al.
Diabetes Care|May 26, 2016
HDL Cholesterol as a Residual Risk Factor for Vascular Events and All-Cause Mortality in Patients With Type 2 DiabetesShahnam Sharif, Yolanda van der Graaf, Hendrik M Nathoe, et al.
Plos One|March 10, 2022
Screen-detected abnormal ankle brachial index: A risk indicator for future cardiovascular morbidity and mortality in patients with manifest cardiovascular diseaseVivianne L Jagt, Constantijn E V B Hazenberg, Jaap Kapelle, et al.
Diabetes Care|March 9, 2022
Estimated Life-Years Gained Free of New or Recurrent Major Cardiovascular Events With the Addition of Semaglutide to Standard of Care in People With Type 2 Diabetes and High Cardiovascular RiskJan Westerink, Kasper Sommer Matthiessen, Solomon Nuhoho, et al.
Pageof 12

Showing results (31-40 of 118) with videos related to

Sort By:
Pageof 12
European Journal of Preventive Cardiology|July 2, 2015
Relationship between recurrent miscarriage and early preterm delivery and recurrent events in patients with manifest vascular disease: The SMART studyKarst Y Heida, Maria Ph Koster, Arie Franx, et al.
Diabetes, Obesity & Metabolism|November 4, 2016
Effect modification in the association between glycated haemoglobin and cardiovascular disease and mortality in patients with type 2 diabetesSanne N van Munster, Yolanda van der Graaf, Harold W de Valk, et al.
Diabetes Care|February 24, 2018
Predicting the Effect of Fenofibrate on Cardiovascular Risk for Individual Patients With Type 2 DiabetesCharlotte Koopal, Frank L J Visseren, Jan Westerink, et al.
The American Journal of Cardiology|January 3, 2015
Effect of statin therapy on incident type 2 diabetes mellitus in patients with clinically manifest vascular diseaseAnton P van de Woestijne, Yolanda van der Graaf, Jan Westerink, et al.
Cardiovascular Diabetology|October 18, 2017
Pioglitazone and the secondary prevention of cardiovascular disease. A meta-analysis of randomized-controlled trialsMarit de Jong, H Bart van der Worp, Yolanda van der Graaf, et al.
BMJ Open|May 19, 2021
Relationship between classic vascular risk factors and cumulative recurrent cardiovascular event burden in patients with clinically manifest vascular disease: results from the UCC-SMART prospective cohort studyTamar Irene de Vries, Jan Westerink, Michiel L Bots, et al.
Journal of the American College of Cardiology|June 21, 2005
Is the association between flow-mediated dilation and cardiovascular risk limited to low-risk populations?Daniel R Witte, Jan Westerink, Eelco J de Koning, et al.
Diabetes Care|May 26, 2016
HDL Cholesterol as a Residual Risk Factor for Vascular Events and All-Cause Mortality in Patients With Type 2 DiabetesShahnam Sharif, Yolanda van der Graaf, Hendrik M Nathoe, et al.
Plos One|March 10, 2022
Screen-detected abnormal ankle brachial index: A risk indicator for future cardiovascular morbidity and mortality in patients with manifest cardiovascular diseaseVivianne L Jagt, Constantijn E V B Hazenberg, Jaap Kapelle, et al.
Diabetes Care|March 9, 2022
Estimated Life-Years Gained Free of New or Recurrent Major Cardiovascular Events With the Addition of Semaglutide to Standard of Care in People With Type 2 Diabetes and High Cardiovascular RiskJan Westerink, Kasper Sommer Matthiessen, Solomon Nuhoho, et al.
Pageof 12